GINA 2021哮喘策略报告:执行摘要与关键更新依据
GINA 2021年度策略报告基于证据更新哮喘管理推荐,强调成人及青少年哮喘不应单用短效β2受体激动剂(SABA),因单用SABA及过度使用存在风险,而吸入性糖皮质激素(ICS)有获益证据。大型试验显示,按需联合ICS-福莫特罗较单用SABA在轻度哮喘中减少严重急性发作≥60%,且急性发作、症状、肺功能及炎症结局与每日ICS加按需SABA相似。指南将成人及青少年治疗图分为两条路径,路径1首选所有步骤使用低剂量ICS-福莫特罗作为缓解剂。
要点
- 成人及青少年哮喘不应单用SABA治疗,因单用及过度使用SABA存在风险。
- 轻度哮喘按需联合ICS-福莫特罗较单用SABA减少严重急性发作≥60%。
- GINA 2021治疗图分两路径,路径1首选所有步骤使用低剂量ICS-福莫特罗作为缓解剂。
核心结论
- GINA推荐成人及青少年哮喘不应单用SABA治疗,因单用SABA及过度使用存在风险且有ICS获益证据。
- 按需联合ICS-福莫特罗在轻度哮喘中较单用SABA减少严重急性发作≥60%。
研究设计与样本
- GINA年度策略报告基于证据更新,本文总结GINA 2021关键推荐及近期变更依据,可适应本地情况如药物可及性。
主要发现
- 大型试验显示按需联合ICS-福莫特罗较单用SABA在轻度哮喘中减少严重急性发作≥60%。
- 按需联合ICS-福莫特罗的急性发作、症状、肺功能及炎症结局与每日ICS加按需SABA相似。
关键数值与推荐
- 路径1(首选)所有步骤以低剂量ICS-福莫特罗为缓解剂:步骤1-2按需仅用,步骤3-5为每日维持ICS-福莫特罗加缓解(MART)。
- 路径2(替代)所有步骤按需SABA,加规律ICS(步骤2)或ICS-长效β2受体激动剂(步骤3-5)。
- 成人中重度哮喘步骤5额外推荐加用长效毒蕈碱拮抗剂和阿奇霉素,重症哮喘加用生物制剂。
- 6-11岁儿童步骤3-4新增治疗选择。
临床怎么用
- 成人及青少年哮喘避免单用SABA,首选路径1以低剂量ICS-福莫特罗为缓解剂。
- 所有年龄及严重度应定期个体化评估、治疗可改变危险因素、自我管理教育、技能培训及适当调整药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting β2-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by ⩾60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, "MART") in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting β2-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.
引用
- Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022. PMID: 34658302. doi:10.1164/rccm.202109-2205PP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。